RenovoRx Q2 net loss $2.3M; positive Phase III data shows 8-month progression delay

RenovoRx, Inc.

2023-Q2 EPS reported -$0.57

Net loss $2.3M vs $2.6M year ago; cash $6.0M; R&D $1.9M, G&A $1.4M.
Phase III TIGeR-PaC: 8-month progression delay, 6-month OS benefit, 65% fewer adverse events.
Collaboration with Imugene to deliver oncolytic immunotherapy via TAMP platform for metastatic disease.
Appointed Robert Spiegel to Board, Margaret Tempero to SAB, Leesa Gentry as SVP Clinical Ops.
Closed $5M registered direct offering and concurrent private placement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.